2020

T3D Therapeutics selects Clinilabs Drug Development Corporation as contract research organization partner for Phase 2 trial of T3D-959 in patients with Alzheimer’s Disease.

December 1, 2020

Webinar: COVID-19 | CNS Clinical Trial Contingency Plans for Sponsors and Investigator Sites

March 23, 2020

Supporting Our Patients and Research Subjects Amidst COVID-19 Concerns

March 10, 2020

Clinilabs Drug Development Corporation Achieves CNS Trial Start-Up in 1/3 the Time of Industry Standard

February 20, 2020

Clinilabs Reduces Patient Outreach Time by 85%

January 22, 2020

When you need to get your product to the people who need it most, your pathway to CNS approval starts with Clinilabs.

Get in Touch